Semaphorin 3B (SEMA3B) induces apoptosis in lung and breast cancer, whereas VEGF165 antagonizes this effect

Emely Castro-Rivera, Sophia Ran, Philip Thorpe, John D. Minna

Research output: Contribution to journalArticle

152 Citations (Scopus)

Abstract

Semaphorin 3B (SEMA3B) is a secreted member of the semaphorin family, important in axonal guidance. We and others have shown that SEMA3B can act as a tumor suppressor by inducing apoptosis either by reexpression in tumor cells or applied as a soluble ligand. The common method of inactivation of SEMA3B is by allele loss and tumor-acquired promoter methylation. We studied the mechanism of SEMA3B-induced tumor cell apoptosis and found that vascular endothelial growth factor (VEGF)165 significantly decreased the proapoptotic and antimitotic effect of transfected or secreted SEMA3B on lung and breast cancer cells. VEGF165 binds to neuropilin, receptors for SEMA3B, and we found that SEMA3B competed for binding of 125I-VEGF165 to lung and breast cancer cells. We also found that small interfering RNA knockdown of tumor-produced VEGF-A or the use of an anti-VEGF neutralizing antibody (Ab) significantly inhibited tumor cell growth in vitro. By contrast, VEGF 121, a VEGF variant that lacks binding to neuropilin (NP)-1 or NP-2 receptors, was not expressed in tumor cells and had no effect on SEMA3B growth-suppressing activities. In conclusion, we hypothesize that VEGF 165, produced by tumor cells, acts as an autocrine survival factor and that SEMA3B, mediates its tumor-suppressing effects, at least in part, by blocking this VEGF autocrine activity.

Original languageEnglish (US)
Pages (from-to)11432-11437
Number of pages6
JournalProceedings of the National Academy of Sciences of the United States of America
Volume101
Issue number31
DOIs
StatePublished - Aug 3 2004

Fingerprint

Semaphorins
Lung Neoplasms
Apoptosis
Breast Neoplasms
Vascular Endothelial Growth Factor A
Neoplasms
Neuropilin-2
Neuropilins
Neuropilin-1
Antimitotic Agents
Growth
Neutralizing Antibodies
Carcinogens
Methylation
Small Interfering RNA
Alleles

ASJC Scopus subject areas

  • Genetics
  • General

Cite this

Semaphorin 3B (SEMA3B) induces apoptosis in lung and breast cancer, whereas VEGF165 antagonizes this effect. / Castro-Rivera, Emely; Ran, Sophia; Thorpe, Philip; Minna, John D.

In: Proceedings of the National Academy of Sciences of the United States of America, Vol. 101, No. 31, 03.08.2004, p. 11432-11437.

Research output: Contribution to journalArticle

@article{9fa95a971a954bd695a23b83213ea390,
title = "Semaphorin 3B (SEMA3B) induces apoptosis in lung and breast cancer, whereas VEGF165 antagonizes this effect",
abstract = "Semaphorin 3B (SEMA3B) is a secreted member of the semaphorin family, important in axonal guidance. We and others have shown that SEMA3B can act as a tumor suppressor by inducing apoptosis either by reexpression in tumor cells or applied as a soluble ligand. The common method of inactivation of SEMA3B is by allele loss and tumor-acquired promoter methylation. We studied the mechanism of SEMA3B-induced tumor cell apoptosis and found that vascular endothelial growth factor (VEGF)165 significantly decreased the proapoptotic and antimitotic effect of transfected or secreted SEMA3B on lung and breast cancer cells. VEGF165 binds to neuropilin, receptors for SEMA3B, and we found that SEMA3B competed for binding of 125I-VEGF165 to lung and breast cancer cells. We also found that small interfering RNA knockdown of tumor-produced VEGF-A or the use of an anti-VEGF neutralizing antibody (Ab) significantly inhibited tumor cell growth in vitro. By contrast, VEGF 121, a VEGF variant that lacks binding to neuropilin (NP)-1 or NP-2 receptors, was not expressed in tumor cells and had no effect on SEMA3B growth-suppressing activities. In conclusion, we hypothesize that VEGF 165, produced by tumor cells, acts as an autocrine survival factor and that SEMA3B, mediates its tumor-suppressing effects, at least in part, by blocking this VEGF autocrine activity.",
author = "Emely Castro-Rivera and Sophia Ran and Philip Thorpe and Minna, {John D.}",
year = "2004",
month = "8",
day = "3",
doi = "10.1073/pnas.0403969101",
language = "English (US)",
volume = "101",
pages = "11432--11437",
journal = "Proceedings of the National Academy of Sciences of the United States of America",
issn = "0027-8424",
number = "31",

}

TY - JOUR

T1 - Semaphorin 3B (SEMA3B) induces apoptosis in lung and breast cancer, whereas VEGF165 antagonizes this effect

AU - Castro-Rivera, Emely

AU - Ran, Sophia

AU - Thorpe, Philip

AU - Minna, John D.

PY - 2004/8/3

Y1 - 2004/8/3

N2 - Semaphorin 3B (SEMA3B) is a secreted member of the semaphorin family, important in axonal guidance. We and others have shown that SEMA3B can act as a tumor suppressor by inducing apoptosis either by reexpression in tumor cells or applied as a soluble ligand. The common method of inactivation of SEMA3B is by allele loss and tumor-acquired promoter methylation. We studied the mechanism of SEMA3B-induced tumor cell apoptosis and found that vascular endothelial growth factor (VEGF)165 significantly decreased the proapoptotic and antimitotic effect of transfected or secreted SEMA3B on lung and breast cancer cells. VEGF165 binds to neuropilin, receptors for SEMA3B, and we found that SEMA3B competed for binding of 125I-VEGF165 to lung and breast cancer cells. We also found that small interfering RNA knockdown of tumor-produced VEGF-A or the use of an anti-VEGF neutralizing antibody (Ab) significantly inhibited tumor cell growth in vitro. By contrast, VEGF 121, a VEGF variant that lacks binding to neuropilin (NP)-1 or NP-2 receptors, was not expressed in tumor cells and had no effect on SEMA3B growth-suppressing activities. In conclusion, we hypothesize that VEGF 165, produced by tumor cells, acts as an autocrine survival factor and that SEMA3B, mediates its tumor-suppressing effects, at least in part, by blocking this VEGF autocrine activity.

AB - Semaphorin 3B (SEMA3B) is a secreted member of the semaphorin family, important in axonal guidance. We and others have shown that SEMA3B can act as a tumor suppressor by inducing apoptosis either by reexpression in tumor cells or applied as a soluble ligand. The common method of inactivation of SEMA3B is by allele loss and tumor-acquired promoter methylation. We studied the mechanism of SEMA3B-induced tumor cell apoptosis and found that vascular endothelial growth factor (VEGF)165 significantly decreased the proapoptotic and antimitotic effect of transfected or secreted SEMA3B on lung and breast cancer cells. VEGF165 binds to neuropilin, receptors for SEMA3B, and we found that SEMA3B competed for binding of 125I-VEGF165 to lung and breast cancer cells. We also found that small interfering RNA knockdown of tumor-produced VEGF-A or the use of an anti-VEGF neutralizing antibody (Ab) significantly inhibited tumor cell growth in vitro. By contrast, VEGF 121, a VEGF variant that lacks binding to neuropilin (NP)-1 or NP-2 receptors, was not expressed in tumor cells and had no effect on SEMA3B growth-suppressing activities. In conclusion, we hypothesize that VEGF 165, produced by tumor cells, acts as an autocrine survival factor and that SEMA3B, mediates its tumor-suppressing effects, at least in part, by blocking this VEGF autocrine activity.

UR - http://www.scopus.com/inward/record.url?scp=3843113186&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3843113186&partnerID=8YFLogxK

U2 - 10.1073/pnas.0403969101

DO - 10.1073/pnas.0403969101

M3 - Article

C2 - 15273288

AN - SCOPUS:3843113186

VL - 101

SP - 11432

EP - 11437

JO - Proceedings of the National Academy of Sciences of the United States of America

JF - Proceedings of the National Academy of Sciences of the United States of America

SN - 0027-8424

IS - 31

ER -